Clinical trials: Tissue Plasminogen Activator, active
Stroke, Acute Ischemic, Endovascular Thrombectomy
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Study Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT.
- Conditions
- Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS
- Trial name
- ACT-REACT (NCT07687056)
- Testing
- Tenecteplase or Alteplase- depending upon availability at each treating centre, Control
- Where
- 13 sites in Australia, Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Calgary
Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis
Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients
Primary Objective: To develop a thrombotic event risk assessment model integrating serum biomarkers (TM, TAT, t-PAIC, PIC) with clinical data, systematically compare its predictive performance across healthy populations, vascular…
- Conditions
- Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis, Dialysis Patients
- Trial name
- TAT-t-PAIC (NCT07098676)
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Ai Peng
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Intracerebral Hemorrhage, Hemorrhagic Risk Conditions
Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is associated with high mortality and long-term disability, and effective treatment options remain limited.
- Conditions
- Intracerebral Hemorrhage, Hemorrhagic Risk Conditions, Bleeding Disorders
- Trial name
- MIMICK-TIPITCH (NCT07411079)
- Testing
- Ex vivo exposure to modified rtPA
- Where
- France
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Stroke, Stroke (in Patients With Atrial Fibrillation)
Thrombolysis in Factor Xa-inhibitors Trial
This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT).
- Conditions
- Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke, Acute Ischemic Stroke
- Trial name
- SIFT (NCT06878066)
- Testing
- thrombolysis therapy
- Where
- 21 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Guri Hagberg
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder
Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]
The purpose of this protocol is to conduct a pilot prospective non-blind clinical trial to evaluate the efficacy and safety of a novel saline irrigation technique as an adjunct to standard interventions for treating retained…
- Conditions
- Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
- Trial name
- [LYTICS+] (NCT06713382)
- Testing
- Pleural Saline Irrigation
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Beth Israel Deaconess Medical Center
Ischemic Stroke
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset.
- Trial name
- AGREE (NCT05910125)
- Testing
- Aspirin, Clopidogrel, Alteplase
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Acute Ischemic Stroke, rhTNK-tPA
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse®) as the control.
- Trial name
- NCT07519889
- Testing
- rhTNK-tPA, rt-PA
- Volunteers
- 4,500 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Ischemic Stroke
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
DO-IT is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (IVT) is safe and improves functional outcome in ischemic stroke patients with recent direct oral…
- Trial name
- DO-IT Cohort (NCT06556446)
- Testing
- Tenecteplase and Alteplase
- Where
- 33 sites in Austria, Belgium and 13 more
- Volunteers
- 2,800 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Eye Diseases, Macular Degeneration, Wet
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces.
- Conditions
- Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
- Trial name
- TIGER (NCT04663750)
- Testing
- Pars plana vitrectomy, Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12, subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- Where
- 42 sites in Germany, Ireland and 5 more
- Volunteers
- 210 people
- Sponsor
- King's College Hospital NHS Trust
Acute Ischemic Stroke
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window
The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic…
- Trial name
- SIMPLIFIED (NCT07606807)
- Testing
- Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pulmonary Embolism Acute
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
High-risk pulmonary embolism is a life-threatening condition requiring immediate reperfusion therapy. Full-dose systemic thrombolysis is recommended as first-line treatment, but its use is limited by the risk of major bleeding…
- Trial name
- REDSTEM (NCT07816978)
- Testing
- Reduced-dose alteplase, Full-dose alteplase
- Where
- 23 sites in Denmark, Norway and 1 more
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Lacunar Stroke, Stroke
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke).
- Conditions
- Lacunar Stroke, Stroke, Ischemic Stroke
- Trial name
- LACUNAR-tPA (NCT07111559)
- Testing
- rt-PA, DAPT
- Where
- 29 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Nippon Medical School
Stroke, Acute Ischemic, Medium Vessel Occlusion
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of IMP-ACT. Acute ischemic stroke (AIS) caused by intracranial arterial occlusion remains a major cause of disability and…
- Trial name
- IMP-ACT (NCT07906275)
- Testing
- Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre
- Where
- 4 sites in Canada
- Volunteers
- 800 people
- Sponsor
- University of Calgary
Acute Respiratory Failure, Hypercoagulability
Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis.
- Conditions
- Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown
- Trial name
- VETtiPAT-ARF (NCT05540834)
- Testing
- Alteplase
- Where
- Australia
- Volunteers
- 70 people
- Sponsor
- South West Sydney Local Health District
Pleural Infection
Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection
Pneumonia, thought to be the chief aetiological process in the development of pleural space infection, is defined as an infection of the lung parenchyma with an estimated annual incidence rate of 5-11 cases per 1000 population…
- Trial name
- ALTON-PI (NCT07432373)
- Testing
- Intrapleural t-PA/Dnase arm, t-PA (Alteplase) 5-10mg and Tyloxapol 200mg
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- National University of Malaysia
Acute Ischemic Stroke, Medium Vessel Occlusion
Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
Medium vessel occlusion (MeVO) accounts for 20-45% of acute ischemic stroke (AIS). Although patients with MeVO often present with relatively low NIHSS scores, up to one-third remain functionally dependent at follow-up despite…
- Trial name
- MeVO-TNK Ⅱ (NCT07302854)
- Testing
- Intra-arterial Thrombolysis, Standard medical treatment
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Xiang Luo
Acute Ischemic Stroke
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
This prospective, multicenter, observational cohort study aims to evaluate the safety and effectiveness of intravenous tenecteplase (rhTNK-tPA) in patients with acute ischemic stroke managed under different transfer models.
- Trial name
- NCT07897955
- Testing
- tenecteplase
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Medical University Union Hospital
Intraventricular Hemorrhage
rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage
The purpose of this pilot study is to determine the safety and optimal dose of clot lysis with rhTNK-tPA for intraventricular hemorrhage, using stereotactic guidance for extraventricular drain placement.
- Trial name
- NCT06814964
- Testing
- Low dose group, Medium dose group, High dose group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Tiantan Hospital